Antiangiogenic biodegradable nanoparticles as an advanced approach to enhance antitumor effects

Combination of antiangiogenic molecules with chemotherapeutics is considered a valuable strategy to increase cancer cell killing through decreased blood supply to the tumor. Our final aim is to develop biodegradable nanoparticles (NPs) which accumulate in cancer cells through folate receptor (FR) and bearing an antiangiogenic anti-FLT1 hexapeptide, which inhibits VEGF-induced endothelial cell migration and angiogenesis. Docetaxel (DTX) was selected as model of poorly water-soluble chemotherapeutics.